Division of Boston Scientific Corp.
Latest From Augmenix Inc.
Femtech, which describes digital technologies that aim to improve women's health, is expected to reach $50bn in market size by 2025, according to Frost & Sullivan. Reproductive health and menstrual health trackers are two of the fastest-growing sectors in femtech. We've highlighted some of the biggest players in both segments, their innovative business models, plans and also looked at barriers such as privacy issues, accuracy of mobile applications and funding challenges.
Augmenix is the privately-held developer of SpaceOAR, an injected hydrogel spacer that is indicated for reducing collateral damage from radiation treatment for prostate cancer. It addresses a market worth about $750m, with total sales expected to reach $90m in 2019.
The company's SpaceOAR injected hydrogel spacer continues to prove effective at reducing the collateral damage from radiation treatment for prostate cancer. Now the Boston company hopes to apply the same bioabsorbable hydrogel technology to improve outcomes with radiation therapy for other cancers, including pancreatic and gynecological cancer.
Only 10 approvals from outside the US were recorded in May in Medtech Insight's approvals tracker. Half of those were for in vitro diagnostics, including three for companion diagnostic for cancer drugs.
- Implantable Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Boston Scientific Corp.
- Senior Management
John Pedersen, Pres. & CEO
Ken Knudson, VP, Global Sales & Mktg.
Pat Campbell, PhD, CTO
David Inman, VP, Fin.
- Contact Info
Phone: (781) 895-3235
201 Burlington Rd.
Bedford, MA 01730
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.